Aptose Bioscns Cmn (APTO) 2.15 $APTO Aptose Sub
Post# of 273241
Posted On: 09/24/2016 7:21:17 AM
Aptose Bioscns Cmn (APTO) 2.15 $APTO
Aptose Submits Formal Response to Clinical Hold for APTO-253
GlobeNewswire - Mon Sep 12, 7:00AM CDT
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, announced today that it has submitted a formal response to the U.S. Food and Drug Administration (FDA) regarding the previously announced clinical hold of Aptose's Phase 1b clinical trial of APTO-253 in patients with hematologic cancers. Aptose provided responses to all of the questions cited in the clinical hold letter issued by the FDA.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences Reports Financial Results for the Second Quarter Ended June 30, 2016
GlobeNewswire - Tue Aug 09, 3:15PM CDT
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced unaudited financial results for the three months ended June 30, 2016 and reported on corporate developments. Unless specified otherwise, all amounts are in Canadian dollars.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences to Present at Canaccord Genuity 36th Annual Growth Conference
GlobeNewswire - Tue Aug 09, 7:00AM CDT
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming Canaccord Genuity 35th Annual Growth Conference on Thursday, August 11th at 2:00 p.m. ET at the InterContinental Hotel Boston, MA. Dr. Rice will provide a corporate overview of the Company's recent activities and strategic direction.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose To Release Second Quarter Ended June 30, 2016 Financial Results and Hold Conference Call on August 9, 2016
GlobeNewswire - Thu Aug 04, 3:15PM CDT
Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2016, on Tuesday, August 9, 2016 after the close of the market. The company intends to host a conference call on the same day at 5:00 p.m. ET to discuss the financial results.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) and CrystalGenomics, Inc. (KOSDAQ:083790) today announced an exclusive global option and license agreement focused on the development of CG026806 (CG'806), a first-in-class, highly potent, non-covalent small molecule inhibitor of the Bruton's tyrosine kinase (BTK), FMS-like tyrosine kinase 3 (FLT3) and the Aurora kinases (AURK). Further to enacting the agreement, Aptose expects to undertake Investigational New Drug (IND) enabling studies immediately, and, if it exercises its option under the agreement, to initiate a Phase 1 clinical trial by mid 2017.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Bioscience Reports Results for the First Quarter Ended March 31, 2016
GlobeNewswire - Tue May 10, 4:10PM CDT
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced unaudited financial results for the three months ended March 31, 2016 and reported on corporate developments. Unless specified otherwise, all amounts are in Canadian dollars.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences reports 1Q loss
Automated Insights - Tue May 10, 3:37PM CDT
MISSISSAUGA, Ontario (AP) _ Aptose Biosciences Inc. (APTO) on Tuesday reported a loss of $3.7 million in its first quarter.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose To Release First Quarter Ended March 31, 2016 Financial Results and Hold Conference Call on May 10, 2016
GlobeNewswire - Mon May 02, 7:00AM CDT
Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended March 31, 2016, on Tuesday, May 10, 2016 after the close of the market. The company intends to host a conference call on the same day at 5:00 p.m. ET to discuss the financial results.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 10.80 (-0.18), ADRO: 14.54 (-0.25), ARWR: 7.22 (-0.05), ADMP: 3.39 (unch), AMGN: 174.80 (-0.82), APTO: 2.15 (unch), AVXL: 3.11 (-0.17), AZN: 33.97 (-0.31), ABBV: 64.98 (-0.10), ARRY: 3.65 (-0.04)
Colon Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbmf4p/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Pipeline Products for Colon Cancer - Overview - Pipeline Products for Colon Cancer - Comparative Analysis - Colon Cancer - Therapeutics under Development by Companies - Colon Cancer - Therapeutics under Investigation by Universities/Institutes - Colon Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colon Cancer - Products under Development by Companies - Colon Cancer - Products under Investigation by Universities/Institutes - Colon Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - ACF Pharmaceuticals, LLC - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aptose Biosciences Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bio-Path Holdings, Inc. - Biogazelle - Bioncotech Therapeutics S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - Carna Biosciences, Inc. - Celyad SA - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/pb...lon_cancer
ADRO: 14.54 (-0.25), AMBX: (), CLBS: 4.88 (+0.25), CANF: 2.63 (-0.05), APTO: 2.15 (unch), AVXL: 3.11 (-0.17), BPTH: 1.39 (-0.05), AZN: 33.97 (-0.31), CYAD: 21.09 (+0.31)
World Prostate Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5qnxq/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Prostate Cancer - Overview - Pipeline Products for Prostate Cancer - Comparative Analysis - Prostate Cancer - Therapeutics under Development by Companies - Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Prostate Cancer - Products under Development by Companies - Prostate Cancer - Products under Investigation by Universities/Institutes - Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - 35 of the 250 Companies - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Acino Pharma AG - Actinium Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - ADC Therapeutics Sarl - Aduro BioTech, Inc. - Advanced Cancer Therapeutics - Advantagene, Inc. - Advaxis, Inc. - Aeglea BioTherapeutics, Inc. - Aeterna Zentaris Inc. - Aileron Therapeutics, Inc. - Akshaya Bio Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - AnGes MG, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antisense Therapeutics Limited - Aphios Corporation - APIM Therapeutics AS - Aptose Biosciences Inc. - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/w5...ate_cancer
ADXS: 10.80 (-0.18), ADRO: 14.54 (-0.25), AMBX: (), ARQL: 1.65 (+0.08), ADMP: 3.39 (unch), AMGN: 174.80 (-0.82), APTO: 2.15 (unch), ATNM: 1.79 (+0.03), AVXL: 3.11 (-0.17), ABBV: 64.98 (-0.10)
CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer
GlobeNewswire - Wed Jan 20, 5:30AM CST
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that it had named Denis R. Burger, Ph.D., who is currently a member of the Company's Board of Directors, as Chief Science Officer (CSO) of CytoDyn. In this capacity, through an expansion of Dr. Burger's existing consulting relationship with the Company, Dr. Burger will assist with the development of PRO 140 for HIV and non-HIV clinical indications, including transplantation, autoimmune diseases and cancer. He recently initiated the Company's evaluation of PRO 140 for Graft vs. Host Disease (GvHD) and the Company's Phase 2 protocol for this transplantation indication for patients requiring bone marrow stem cell transplants. On December 11, 2015, the FDA cleared CytoDyn to proceed into a clinical trial for GvHD. PRO 140 is currently in a pivotal Phase 3 trial for adjunct therapy for HIV patients with FDA approval for this indication expected in 2017.
APTO: 2.15 (unch), TRIB: 12.68 (+0.04), OSUR: 8.31 (-0.18)
Aptose Biosciences Inc. Market - Global Product Pipeline Review - 2015
M2 - Wed Dec 16, 4:55AM CST
Summary
APTO: 2.15 (unch)
Moffitt Cancer Center and Aptose Biosciences to Present Data on a Novel Class of Dual-Targeting Bromodomain / Kinase Inhibitors at 57th Annual American Society of Hematology (ASH) Meeting
GlobeNewswire - Thu Dec 03, 7:00AM CST
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that its collaborator, Moffitt Cancer Center, will present preclinical data for its dual-targeting bromodomain (BRD) / kinase inhibitor, MA2-014, at the 57th Annual American Society of Hematology (ASH) Meeting and Exposition being held December 5-8, 2015, in Orlando, FL.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire - Mon Nov 30, 4:00PM CST
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming investor conferences:
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Voluntarily Suspends Clinical Dosing of APTO-253 to Review Drug Manufacturing Processes and Procedures
GlobeNewswire - Fri Nov 20, 6:30AM CST
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) (Aptose or the Company), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that the Food and Drug Administration (FDA), following a voluntary suspension of dosing by the Company and discussions with the Company, placed the Phase Ib clinical trial of APTO-253 in patients with hematologic cancers on clinical hold. This hold is intended to ensure patient safety on the trial and to ensure manufacturing and dosing procedures are consistent with the appropriate documented quality standards.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences Reports Results for the Third Quarter Ended September 30, 2015
GlobeNewswire - Tue Nov 10, 3:06PM CST
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today reported financial results for the three months ended September 30, 2015 and provided a corporate update. Unless specified otherwise, all amounts are in Canadian dollars.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences Announces Collaborations for New Multi-Targeting Epigenetic Therapeutic Agents
GlobeNewswire - Tue Nov 10, 7:30AM CST
Moffitt Cancer Center Grants Aptose Exclusive Global Rights to Highly Potent Multi-Targeting Epigenetic Inhibitors
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences Inc. - Product Pipeline Review - 2015
PR Newswire - Mon Nov 09, 2:32PM CST
Summary
APTO: 2.15 (unch)
Aptose Submits Formal Response to Clinical Hold for APTO-253
GlobeNewswire - Mon Sep 12, 7:00AM CDT
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, announced today that it has submitted a formal response to the U.S. Food and Drug Administration (FDA) regarding the previously announced clinical hold of Aptose's Phase 1b clinical trial of APTO-253 in patients with hematologic cancers. Aptose provided responses to all of the questions cited in the clinical hold letter issued by the FDA.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences Reports Financial Results for the Second Quarter Ended June 30, 2016
GlobeNewswire - Tue Aug 09, 3:15PM CDT
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced unaudited financial results for the three months ended June 30, 2016 and reported on corporate developments. Unless specified otherwise, all amounts are in Canadian dollars.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences to Present at Canaccord Genuity 36th Annual Growth Conference
GlobeNewswire - Tue Aug 09, 7:00AM CDT
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming Canaccord Genuity 35th Annual Growth Conference on Thursday, August 11th at 2:00 p.m. ET at the InterContinental Hotel Boston, MA. Dr. Rice will provide a corporate overview of the Company's recent activities and strategic direction.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose To Release Second Quarter Ended June 30, 2016 Financial Results and Hold Conference Call on August 9, 2016
GlobeNewswire - Thu Aug 04, 3:15PM CDT
Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2016, on Tuesday, August 9, 2016 after the close of the market. The company intends to host a conference call on the same day at 5:00 p.m. ET to discuss the financial results.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) and CrystalGenomics, Inc. (KOSDAQ:083790) today announced an exclusive global option and license agreement focused on the development of CG026806 (CG'806), a first-in-class, highly potent, non-covalent small molecule inhibitor of the Bruton's tyrosine kinase (BTK), FMS-like tyrosine kinase 3 (FLT3) and the Aurora kinases (AURK). Further to enacting the agreement, Aptose expects to undertake Investigational New Drug (IND) enabling studies immediately, and, if it exercises its option under the agreement, to initiate a Phase 1 clinical trial by mid 2017.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Bioscience Reports Results for the First Quarter Ended March 31, 2016
GlobeNewswire - Tue May 10, 4:10PM CDT
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced unaudited financial results for the three months ended March 31, 2016 and reported on corporate developments. Unless specified otherwise, all amounts are in Canadian dollars.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences reports 1Q loss
Automated Insights - Tue May 10, 3:37PM CDT
MISSISSAUGA, Ontario (AP) _ Aptose Biosciences Inc. (APTO) on Tuesday reported a loss of $3.7 million in its first quarter.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose To Release First Quarter Ended March 31, 2016 Financial Results and Hold Conference Call on May 10, 2016
GlobeNewswire - Mon May 02, 7:00AM CDT
Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended March 31, 2016, on Tuesday, May 10, 2016 after the close of the market. The company intends to host a conference call on the same day at 5:00 p.m. ET to discuss the financial results.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 10.80 (-0.18), ADRO: 14.54 (-0.25), ARWR: 7.22 (-0.05), ADMP: 3.39 (unch), AMGN: 174.80 (-0.82), APTO: 2.15 (unch), AVXL: 3.11 (-0.17), AZN: 33.97 (-0.31), ABBV: 64.98 (-0.10), ARRY: 3.65 (-0.04)
Colon Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbmf4p/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Pipeline Products for Colon Cancer - Overview - Pipeline Products for Colon Cancer - Comparative Analysis - Colon Cancer - Therapeutics under Development by Companies - Colon Cancer - Therapeutics under Investigation by Universities/Institutes - Colon Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colon Cancer - Products under Development by Companies - Colon Cancer - Products under Investigation by Universities/Institutes - Colon Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - ACF Pharmaceuticals, LLC - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aptose Biosciences Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bio-Path Holdings, Inc. - Biogazelle - Bioncotech Therapeutics S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - Carna Biosciences, Inc. - Celyad SA - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/pb...lon_cancer
ADRO: 14.54 (-0.25), AMBX: (), CLBS: 4.88 (+0.25), CANF: 2.63 (-0.05), APTO: 2.15 (unch), AVXL: 3.11 (-0.17), BPTH: 1.39 (-0.05), AZN: 33.97 (-0.31), CYAD: 21.09 (+0.31)
World Prostate Cancer Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5qnxq/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Prostate Cancer - Overview - Pipeline Products for Prostate Cancer - Comparative Analysis - Prostate Cancer - Therapeutics under Development by Companies - Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Prostate Cancer - Products under Development by Companies - Prostate Cancer - Products under Investigation by Universities/Institutes - Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - 35 of the 250 Companies - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Acino Pharma AG - Actinium Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - ADC Therapeutics Sarl - Aduro BioTech, Inc. - Advanced Cancer Therapeutics - Advantagene, Inc. - Advaxis, Inc. - Aeglea BioTherapeutics, Inc. - Aeterna Zentaris Inc. - Aileron Therapeutics, Inc. - Akshaya Bio Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - AnGes MG, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antisense Therapeutics Limited - Aphios Corporation - APIM Therapeutics AS - Aptose Biosciences Inc. - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/w5...ate_cancer
ADXS: 10.80 (-0.18), ADRO: 14.54 (-0.25), AMBX: (), ARQL: 1.65 (+0.08), ADMP: 3.39 (unch), AMGN: 174.80 (-0.82), APTO: 2.15 (unch), ATNM: 1.79 (+0.03), AVXL: 3.11 (-0.17), ABBV: 64.98 (-0.10)
CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer
GlobeNewswire - Wed Jan 20, 5:30AM CST
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that it had named Denis R. Burger, Ph.D., who is currently a member of the Company's Board of Directors, as Chief Science Officer (CSO) of CytoDyn. In this capacity, through an expansion of Dr. Burger's existing consulting relationship with the Company, Dr. Burger will assist with the development of PRO 140 for HIV and non-HIV clinical indications, including transplantation, autoimmune diseases and cancer. He recently initiated the Company's evaluation of PRO 140 for Graft vs. Host Disease (GvHD) and the Company's Phase 2 protocol for this transplantation indication for patients requiring bone marrow stem cell transplants. On December 11, 2015, the FDA cleared CytoDyn to proceed into a clinical trial for GvHD. PRO 140 is currently in a pivotal Phase 3 trial for adjunct therapy for HIV patients with FDA approval for this indication expected in 2017.
APTO: 2.15 (unch), TRIB: 12.68 (+0.04), OSUR: 8.31 (-0.18)
Aptose Biosciences Inc. Market - Global Product Pipeline Review - 2015
M2 - Wed Dec 16, 4:55AM CST
Summary
APTO: 2.15 (unch)
Moffitt Cancer Center and Aptose Biosciences to Present Data on a Novel Class of Dual-Targeting Bromodomain / Kinase Inhibitors at 57th Annual American Society of Hematology (ASH) Meeting
GlobeNewswire - Thu Dec 03, 7:00AM CST
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that its collaborator, Moffitt Cancer Center, will present preclinical data for its dual-targeting bromodomain (BRD) / kinase inhibitor, MA2-014, at the 57th Annual American Society of Hematology (ASH) Meeting and Exposition being held December 5-8, 2015, in Orlando, FL.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire - Mon Nov 30, 4:00PM CST
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the upcoming investor conferences:
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Voluntarily Suspends Clinical Dosing of APTO-253 to Review Drug Manufacturing Processes and Procedures
GlobeNewswire - Fri Nov 20, 6:30AM CST
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) (Aptose or the Company), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that the Food and Drug Administration (FDA), following a voluntary suspension of dosing by the Company and discussions with the Company, placed the Phase Ib clinical trial of APTO-253 in patients with hematologic cancers on clinical hold. This hold is intended to ensure patient safety on the trial and to ensure manufacturing and dosing procedures are consistent with the appropriate documented quality standards.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences Reports Results for the Third Quarter Ended September 30, 2015
GlobeNewswire - Tue Nov 10, 3:06PM CST
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today reported financial results for the three months ended September 30, 2015 and provided a corporate update. Unless specified otherwise, all amounts are in Canadian dollars.
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences Announces Collaborations for New Multi-Targeting Epigenetic Therapeutic Agents
GlobeNewswire - Tue Nov 10, 7:30AM CST
Moffitt Cancer Center Grants Aptose Exclusive Global Rights to Highly Potent Multi-Targeting Epigenetic Inhibitors
APTO: 2.15 (unch), APS.TO: 2.87 (+0.07)
Aptose Biosciences Inc. - Product Pipeline Review - 2015
PR Newswire - Mon Nov 09, 2:32PM CST
Summary
APTO: 2.15 (unch)
(0)
(0)Scroll down for more posts ▼